Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.

Abstract:

PURPOSE:To develop a limited sampling strategy (LSS) to predict area under the concentration-time curve (AUC) ratios of omeprazole (AUC(OPZ)) to its metabolites 5-hydroxyomeprazole (AUC(5OH)) and omeprazole sulfone (AUC(SUL)) as phenotyping parameters for cytochrome P450 (CYP) 2C19 and 3A. METHODS:Data were obtained from 37 (4 women) Caucasian, Chinese, and Korean healthy adults from three published studies. The AUC(OPZ), AUC(5OH), and AUC(SUL) were calculated via noncompartmental analysis. Observed AUC(OPZ, OBS)/AUC(5OH, OBS) and AUC(OPZ, OBS)/AUC(SUL, OBS) were determined. Plasma concentrations of omeprazole, 5-hydroxyomeprazole, and omeprazole sulfone at 1, 1.5, 2, 3, 4, 6, and 8 h post-dose were used to generate limited sampling strategy (LSS) models to predict AUC(OPZ,PRE)/AUC(5OH,PRE) and AUC(OPZ,PRE/)AUC(SUL,PRE). Bias and precision were assessed via percentage mean prediction error (%MPE) and percentage mean absolute error (%MAE), with acceptable limits being <15%. RESULTS:For CYP2C19, the AUC(OPZ,OBS)/AUC(5OH,OBS) was [mean ± standard deviation (SD)] 2.10 ± 1.63. Five LSS models of AUC(OPZ,PRE)/AUC(5OH,PRE) were generated, but none met the bias or precision criteria. Upon stratification by CYP2C19 genotype and ethnicity, a three-timepoint (at 1, 2, and 4 h) LSS model accurately predicted AUC(OPZ)/AUC(5OH) in Caucasian CYP2C19*1/*1 subjects. For CYP3A, AUC(OPZ,OBS)/AUC(SUL,OBS) (mean ± SD) was 1.79 ± 0.67. All LSS models had unacceptable %MAE, even when stratified by CYP2C19 genotype and ethnicity. CONCLUSIONS:A LSS model to predict AUC(OPZ)/AUC(5OH), and thus CYP2C19 activity, was generated for Caucasian CYP2C19*1/*1 subjects. However, additional model validation is needed prior to general use. LSS models to predict AUC(OPZ)/AUC(SUL), and thus CYP3A activity, were not possible, even upon stratification by CYP2C19 genotype and ethnicity.

journal_name

Eur J Clin Pharmacol

authors

Lawson EB,Wu JC,Baldwin RM,Ingelman-Sundberg M,Rosenborg S,Yim DS,Yin OQ,Capparelli EV,Ma JD

doi

10.1007/s00228-011-1136-y

subject

Has Abstract

pub_date

2012-04-01 00:00:00

pages

407-13

issue

4

eissn

0031-6970

issn

1432-1041

journal_volume

68

pub_type

临床试验,杂志文章
  • Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers.

    abstract:INTRODUCTION:Deoxycytidine kinase (DCK) is the rate-limiting enzyme of the intracellular phosphorylation of nucleoside anticancer drugs, including gemcitabine and beta-arabinofuranosylcytosine, to their active triphosphates. This study was performed to assess the occurrence and frequency of DCK polymorphisms in a predo...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-006-0162-7

    authors: Joerger M,Bosch TM,Doodeman VD,Beijnen JH,Smits PH,Schellens JH

    更新日期:2006-08-01 00:00:00

  • Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009.

    abstract:PURPOSE:Spontaneous reporting systems in European countries are crucial for collecting adverse drug reaction (ADR) reports. The aim of this study was to evaluate reporting activity among countries and their strategy to increase the number of reports. We also established the best measure for assessment quantity of repor...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-012-1219-4

    authors: Srba J,Descikova V,Vlcek J

    更新日期:2012-07-01 00:00:00

  • Paracetamol test: modification by renal function, urine flow and pH.

    abstract::Factors which might affect paracetamol disposition have been studied in a heterogenous group of patients in need of mild analgesia in an intensive care unit. Following oral administration of 1 g of paracetamol, plasma and urinary concentrations of the parent compound and metabolites were assessed by HPLC. The renal cl...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00315104

    authors: Kietzmann D,Bock KW,Krähmer B,Kettler D,Bircher J

    更新日期:1990-01-01 00:00:00

  • Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring.

    abstract::The incidence of vasodilation-related events (flushing, headache, dizziness and oedema) was determined in a total of 37,670 patients treated with diltiazem, nicardipine, isradipine or amlodipine and studied by Prescription-Event Monitoring between 1984 and 1991. Event rates are expressed as the percentage of patients ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00202163

    authors: Kubota K,Pearce GL,Inman WH

    更新日期:1995-01-01 00:00:00

  • Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients.

    abstract:AIM:Mizoribine (MZR) is an immunosuppressant for the prevention of allograft rejection in Asian countries, but the great variability in pharmacokinetics (PK) limits its clinical use. This study was to explore genetic and clinical factors that affect the MZR PK process. METHODS:Blood samples and clinical data were coll...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-020-02936-7

    authors: Dai R,Li J,Wu J,Fu Q,Yan J,Zhong G,Wang C,Chen X,Chen P

    更新日期:2021-01-01 00:00:00

  • Sublingual and oral isoxsuprine in patients with Raynaud's phenomenon.

    abstract::Oral and sublingual isoxsuprine 20 mg were compared with placebo in double blind randomised cross over trial in 7 patients with Raynaud's phenomenon. Skin thermography, plethysmography of the finger tips and direct temperature measurements showed that sublingual isoxsuprine was slightly but consistently superior to th...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00615400

    authors: Wesseling H,den Heeten A,Wouda AA

    更新日期:1981-01-01 00:00:00

  • Safety and efficacy of tolcapone in Parkinson's disease: systematic review.

    abstract:PURPOSE:Tolcapone is an efficacious catechol-O-methyltransferase inhibitor for Parkinson's disease (PD). However, safety issues hampered its use in clinical practice. We aimed to provide evidence of safety and efficacy of tolcapone by a systematic literature review to support clinicians' choices in the use of an enlarg...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00228-020-03081-x

    authors: Artusi CA,Sarro L,Imbalzano G,Fabbri M,Lopiano L

    更新日期:2021-01-07 00:00:00

  • Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

    abstract::We have evaluated the effects of repaglinide, a new non-sulphonylurea oral hypoglycaemic agent that has a stimulatory effect on insulin secretion. Forty-four patients with NIDDM, already treated with a sulphonylurea, took part in an open, randomised, group comparison study of 12 weeks duration, during which they recei...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00315490

    authors: Wolffenbuttel BH,Nijst L,Sels JP,Menheere PP,Müller PG,Kruseman AC

    更新日期:1993-01-01 00:00:00

  • Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.

    abstract:PURPOSE:Pre-clinical experiments have shown that almorexant, a dual orexin receptor antagonist, is able to inhibit cytochrome P450 3A4 (CYP3A4). Therefore, a study was conducted to investigate the effects of multiple-dose almorexant on the pharmacokinetics of midazolam and simvastatin, two CYP3A4 model substrates. MET...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-012-1403-6

    authors: Hoch M,Hoever P,Alessi F,Theodor R,Dingemanse J

    更新日期:2013-03-01 00:00:00

  • Initial clinical experience of lorcainide (Ro 13-1042), a new antiarrhythmic agent.

    abstract::Lorcainide is a promising antiarrhythmic agent that belongs to the class of local anesthetics. It was tested in 7 patients with malignant ventricular arrhythmias that were resistant to other antiarrhythmic agents. Lorcainide was effective in all cases (complete disappearance of arrhythmias in 6 cases and more than 50%...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00607440

    authors: Cocco G,Strozzi C

    更新日期:1978-11-16 00:00:00

  • Suppression of respiratory burst of polymorphonuclear leukocytes by azelastine hydrochloride (Azeptin).

    abstract::The inhibitory action of azelastine hydrochloride (Azeptin) on the respiratory burst in peripheral polymorphonuclear leukocytes (PMN) and pulmonary alveolar macrophages (PAM) has been studied. Azeptin in vitro suppressed chemiluminescence and superoxide (O2-) generation by human PMN in a dose- and time-dependent manne...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00194963

    authors: Ueta E,Osaki T,Kawasaki N,Nomura Y

    更新日期:1994-01-01 00:00:00

  • Prazosin depression of baroreflex function in hypertensive man.

    abstract::Prazosin is a post synaptic alpha adrenergic blocker effective in hypertension, whose hypotensive effect is unaccompanied by reflex tachycardia or hyperreninemia, nor by other evidence of increased sympathetic activity. We studied the baroreceptor reflex arc as a potential mediator of these effects. Twenty-two essenti...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00606418

    authors: Sasso EH,O'Connor DT

    更新日期:1982-01-01 00:00:00

  • Inhibition of pentagastrin-stimulated gastric acid secretion and plasma levels of the new histamine H2-receptor antagonist ramixotidine dihydrochloride (CM 57755) in human volunteers.

    abstract::The new competitive histamine H2-receptor antagonist, ramixotidine 2 HCl (CM 57755), has been tested in healthy male volunteers for its ability to inhibit pentagastrin-stimulated gastric acid secretion. In the first study, in 8 subjects, pentagastrin 6 micrograms.kg-1 was injected s.c., 90 min after the following 4 or...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00637671

    authors: Brassinne A,Dresse A,Basilisco G,Manara L

    更新日期:1987-01-01 00:00:00

  • Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.

    abstract::Quinidine is a very potent inhibitor of CYP2D6, but the role of the enzyme in the biotransformation of quinidine has only been investigated in a single in vitro study and in two small in vivo experiments, with contradictory results. The present investigation was designed to present definite evaluation of whether quini...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00194341

    authors: Nielsen F,Rosholm JU,Brøsen K

    更新日期:1995-01-01 00:00:00

  • Plasma renin concentration in essential hypertension during beta-adrenergic blockade and vasodilator therapy.

    abstract::Plasma renin concentration (PRC) was measured in 46 patients with essential hypertension before and after treatment for 4 weeks with alprenolol 600-1200 mg daily. In 27 of these patients PRC was measured after 4 weeks of combined treatment with alprenolol and hydralizine. During alprenolol treatment PRC and blood pres...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00645128

    authors: Pedersen EB,Kornerup HJ

    更新日期:1977-10-14 00:00:00

  • Dropout rates with olanzapine or risperidone: a multi-centre observational study.

    abstract:OBJECTIVE:In patients with schizophrenia, risperidone and olanzapine are the two most commonly used atypical anti-psychotics. A recent meta-analysis based on randomized trials suggests that, in the long term, olanzapine can have a lower frequency of treatment discontinuation (or dropout) in comparison with risperidone....

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-003-0705-0

    authors: Pelagotti F,Santarlasci B,Vacca F,Trippoli S,Messori A

    更新日期:2004-02-01 00:00:00

  • Variability of beta-blocker pharmacokinetics in young volunteers.

    abstract::Plasma concentrations of metoprolol, propranolol oxprenolol, acebutolol and its metabolite diacetolol were measured after single oral doses in young health volunteers. In order to assessed the inter- and intra-subject variability the following pharmacokinetic parameters were compared: AUC0(24), Cmax, tmax and t 1/2. T...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF01061375

    authors: Jack DB,Quarterman CP,Zaman R,Kendall MJ

    更新日期:1982-01-01 00:00:00

  • Pharmacokinetics of ethanol in plasma and whole blood: estimation of total body water by the dilution principle.

    abstract::The pharmacokinetics of ethanol in plasma and whole blood have been investigated and the results used to estimate the volume of total body water (TBW) by means of the dilution principle. Fifteen men (mean age 62 y) were given 0.6 g ethanol/kg body weight as an intravenous infusion over 1 h. The peak concentration of e...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00280133

    authors: Jones AW,Hahn RG,Stalberg HP

    更新日期:1992-01-01 00:00:00

  • Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability.

    abstract:PURPOSE:Propofol anesthesia is usually accompanied by hypotensive responses, which are at least in part mediated by nitric oxide (NO). Arginase I (ARG1) and arginase II (ARG2) compete with NO synthases for their common substrate L-arginine, therefore influencing the NO formation. We examined here whether ARG1 and ARG2 ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-020-03059-9

    authors: Oliveira-Paula GH,Coeli-Lacchini FB,Ferezin LP,Ferreira GC,Pinheiro LC,Paula-Garcia WN,Garcia LV,Tanus-Santos JE,Lacchini R

    更新日期:2021-01-07 00:00:00

  • Clinical experience of encainide (MJ 9067): a new anti-arrhythmic drug.

    abstract::Encainide is a new anti-arrhythmic drug, which is highly effective against ventricular extrasystoles, both single and coupled, in the dose range of 80--140 mg i.v. Ventricular extrasystoles were abolished in 31 out of 33 cases treated. The drug is also relatively effective against supraventricular extrasystoles, but h...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00605629

    authors: Kesteloot H,Stroobandt R

    更新日期:1979-11-01 00:00:00

  • Acute effects of trimetazidine evaluated by exercise testing.

    abstract::A single dose of 60 mg trimetazidine (the normal daily dose) improved exercise capacity in angina pectoris, as reflected by an increase in the duration of exercise, total work performed, and improvement in ECG signs of ischaemia. All these effects occurred without any detectable chronotropic or vasomotor effect. The i...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00544569

    authors: Sellier P,Audouin P,Payen B,Corona P,Duong TC,Ourbak P

    更新日期:1987-01-01 00:00:00

  • Cardiovascular and respiratory effects of the beta-adrenoceptive antagonist sotalol: studies in health, angina pectoris and obstructive lung disease.

    abstract::The cardiovascular and respiratory actions of the adrenergic beta adrenoceptive drug sotalol have been studied in an open, short term trial. Fifteen patients with angina performed standardized orthostatic and exercise tests before and after injection of 20 mg sotalol intravenously. Although there was a significant red...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00562313

    authors: Areskog NH,Cullhed I,Ringqvist I,Ström G

    更新日期:1975-08-14 00:00:00

  • Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation.

    abstract:PURPOSES:Tacrolimus (TAC) is the most widely used immunosuppressant for the prevention of acute rejection after solid organ transplantation. Its pharmacokinetics (PK) show considerable variability, making TAC a good candidate for therapeutic drug monitoring (TDM). The principal aim of the study was to describe the PK o...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-013-1501-0

    authors: Guy-Viterbo V,Scohy A,Verbeeck RK,Reding R,Wallemacq P,Musuamba FT

    更新日期:2013-08-01 00:00:00

  • A collaborative intervention to improve surgical antibiotic prophylaxis in children: results from a prospective multicenter study.

    abstract:PURPOSE:The use of surgical antibiotic prophylaxis (SAP) in children is poorly characterized. Our aim was to evaluate the effectiveness of a quality improvement (QI) intervention targeting SAP in children, by means of a multicenter prospective intervention study, with a before and after design. METHODS:We prospectivel...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s00228-017-2270-y

    authors: Ciofi Degli Atti M,Alegiani SS,Raschetti R,Arace P,Giusti A,Spiazzi R,Raponi M,APACHE Study Group.

    更新日期:2017-09-01 00:00:00

  • Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia.

    abstract:PURPOSE:The purpose of the present study was to examine the relationship between the incidence of hyperammonemia and changes in the prescribing of concomitant antiepileptic drugs (AEDs) in patients receiving valproic acid. METHODS:We evaluated 40,363 plasma samples from 6009 epilepsy patients obtained from 2006 to 201...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-015-1939-3

    authors: Yamamoto Y,Takahashi Y,Imai K,Mishima N,Kagawa Y,Inoue Y

    更新日期:2015-12-01 00:00:00

  • Comparison of the pharmacokinetics of glipizide and glibenclamide in man.

    abstract::Four subjects received 5 mg 14C-glipizide orally, 3 subjects 1 mg intravenously and 2 subjects 5 mg 14C-glibenclamide orally. Plasma levels of radioactivity, and urinary and faecal excretion were measured. For both drugs the disappearance of radioactivity from plasma followed complex kinetics and the apparent half-liv...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00616416

    authors: Balant L,Fabre J,Zahnd GR

    更新日期:1975-01-01 00:00:00

  • Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.

    abstract::Thirty patients suffering from essential hypertension were treated successively with placebo, hydralazine alone, and pindolol (Visken) combined with hydralazine. Hydralazine caused a statistically significant reduction in blood pressure and an increase in pulse rate as compared with the placebo: palpitations were an i...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00614002

    authors: Persson I

    更新日期:1975-12-19 00:00:00

  • Mechanism of the interaction of propranolol and a potent vasodilator antihypertensive agent - minoxidil.

    abstract::A study, using non-invasive techniques, was carried out in ten patients with essential hypertension to examine the mechanism of the hypotensive effect of propranolol when used in combination with a potent vasodilator antihypertensive - minoxidil. The hypotensive effect of minoxidil, a mean (+/- SEM) decrease of 42.4 +...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00606548

    authors: O'Malley K,Velasco M,Wells J,McNay J

    更新日期:1976-03-22 00:00:00

  • Inhibition of the aldosterone response to sodium depletion in man by stimulation of dopamine DA2 receptors.

    abstract::In this study we have investigated the effect of co-dergocrine, a selective DA2-agonist, on plasma aldosterone concentrations (PAC) in twelve patients with essential hypertension both in basal conditions and during sodium depletion. Sodium depletion resulted in an increase of PAC from 38 (13) pg/ml to 297 (21) pg/ml. ...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00558273

    authors: Lombardi C,Missale C,De Cotiis R,Spedini C,Pizzoccolo G,Memo M,Albertini A,Spano PF

    更新日期:1988-01-01 00:00:00

  • Regional distribution of beta 1- and beta 2-adrenoceptors in the failing and nonfailing human heart.

    abstract::Total beta-adrenoceptor density and beta 1- and beta 2-subtype distribution in right and left atria and in different ventricular regions from 14 failing and seven nonfailing human hearts have been compared. End-stage heart failure was due to idiopathic dilated cardiomyopathy (n = 8) or ischaemic cardiomyopathy (n = 6)...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00265923

    authors: Steinfath M,Lavicky J,Schmitz W,Scholz H,Döring V,Kalmár P

    更新日期:1992-01-01 00:00:00